A Phase II Randomized, Open-Label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ethambutol; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampicin; Rifapentine
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Apr 2017 Biomarkers information updated
- 03 Apr 2013 Planned end date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 03 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.